Nephros (NEPH)
(Delayed Data from NSDQ)
$2.29 USD
+0.14 (6.51%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $2.30 +0.01 (0.44%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NEPH 2.29 +0.14(6.51%)
Will NEPH be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NEPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NEPH
Nephros Inc. (NEPH) Reports Q3 Loss, Misses Revenue Estimates
Lantheus Holdings (LNTH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
NEPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Nephros Inc. (NEPH) Report Negative Earnings Next Week? What You Should Know
Nephros Inc. (NEPH) Reports Q2 Loss, Tops Revenue Estimates
Other News for NEPH
GEE Group And 2 Other Stocks Under $3 Insiders Are Buying
Insider Buying: President and CEO Banks Robert R. Jr. Acquires 50,000 Shares of Nephros Inc (NEPH)
Novavax, Capricor Therapeutics, Arcutis Biotherapeutics among healthcare movers
Nephros: Buy Rating Affirmed Amid Solid Performance and Growth Prospects
Nephros files $50M mixed securities shelf